Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
Posted on29 Nov 2018
Comments0
The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult... Read More
Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
USFDA granted 6-month pediatric exclusivity to Lyrica, which helps to Lyrica to extent the patent expiration by additional 6 month. Lyrica received... Read More
What is pediatric exclusivity?
Posted on29 Nov 2018
Comments0
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and may run concurrently with a patent but... Read More
Case Study: Insight on DRL-Indivior Suboxone Patent Battle
June 2018 : DRL got the generic approval for Suboxone Dr Reddy’ s Laboratories received approval from the USFDA for generic version... Read More
Grünenthal entering into US market with acquisition of US based Averitas Pharma
Grünenthal has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be... Read More
Pharma Disinvestment deal: AstraZeneca to divest Synagis US rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused... Read More
Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
Daiichi Sankyo Company, Limited announced that Daiichi Sankyo and GlaxoSmithKline K.K have agreed to dissolve their joint venture company, Japan Vaccine Co,... Read More
Insight on Strides – SUDA Pharma Strategic Deal
Strides Pharma Science’s wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK’s Breo Ellipta generics
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close... Read More